Loading organizations...
Based in Needham, Massachusetts, Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies for rare and orphan diseases. The organization utilizes a specialized transient permeability enhancer technology platform to convert complex treatments traditionally administered by injection into accessible, daily oral medications. Its lead commercial product, MYCAPSSA, is an oral octreotide capsule specifically designed for the long-term maintenance treatment of patients suffering from acromegaly and other serious chronic conditions. Following the successful completion of Phase III clinical trials for this primary therapeutic asset, the enterprise entered into a definitive merger agreement to expand its global commercial reach. On May 5, 2021, the business was officially acquired by Amryt Pharma plc, a global biopharmaceutical corporation operating within the same rare disease sector. The biopharmaceutical enterprise was originally founded in 2001 by an unlisted founding team.
Chiasma has raised $161.0M across 4 funding rounds.
Chiasma has raised $161.0M in total across 4 funding rounds.
Chiasma has raised $161.0M across 4 funding rounds. Most recently, it raised $70.0M Series E in February 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2015 | $70M Series E | — | Abingworth, ARCH Venture Partners, MPM Capital, Norwest Venture Partners, Pureos Bioventures, 7 MED Health Ventures, F2 Venture Capital, Rock Springs Capital, Sofinnova Investments | Announced |
| Jul 1, 2012 | $39M Series D | Abingworth, MPM Capital | ARCH Venture Partners, Norwest Venture Partners, Pureos Bioventures, Fredric Price, 7 MED Health Ventures, F3 Ventures | Announced |
| Nov 1, 2006 | $44M Series C | — | Abingworth, ARCH Venture Partners, MPM Capital, Norwest Venture Partners, Pureos Bioventures | Announced |
| Sep 1, 2005 | $8M Series B | — | Abingworth, ARCH Venture Partners, MPM Capital | Announced |
Chiasma has raised $161.0M in total across 4 funding rounds.
Chiasma's investors include Abingworth, ARCH Venture Partners, MPM Capital, Norwest Venture Partners, Pureos Bioventures, 7 Med Health Ventures, F2 Venture Capital, Rock Springs Capital, Sofinnova Ventures, Fredric Price, F3 Ventures.
Chiasma, Inc. is a commercial-stage biopharmaceutical company specializing in oral formulations of peptide and protein drugs using its proprietary Transient Permeability Enhancer (TPE™) technology.[1][2][3][4] It develops products that convert injectable therapies to oral versions, such as Mycapssa, the first FDA-approved oral somatostatin analog capsule for acromegaly, targeting patients with rare chronic diseases by improving treatment convenience and potentially reducing side effects.[1][2][3] The company serves patients facing injection-related challenges, solving key problems in drug delivery for peptides, with demonstrated growth through $185.8M in total funding across three rounds, including a $75M recent raise, and partnerships like Merck recognizing its oral peptide potential.[1][2]
Chiasma emerged as a biopharma innovator focused on proprietary technology to reformulate approved drugs into oral forms, enabling switches from injectables and exploring new indications.[2][3][4] Headquartered in Newton Center, Massachusetts, with around 106 employees and revenue under $5M, it built early traction by advancing TPE™ for peptide delivery, culminating in Mycapssa's approval as a pioneering oral therapy for acromegaly.[1][2][3] Pivotal moments include securing substantial funding and industry validation, positioning it to address unmet needs in rare disease treatments, though specific founders or exact founding year details are not detailed in available records.[2][5]
Chiasma rides the trend toward oral peptide therapeutics in biopharma, addressing the $100B+ injectable peptide market by enabling patient-friendly alternatives amid rising demand for convenient chronic disease management.[1][2][3] Timing aligns with FDA approvals for novel formulations and investor interest in rare disease drugs, bolstered by market forces like aging populations and injection fatigue.[1][4][5] It influences the ecosystem by pioneering TPE™, inspiring similar tech in women's health and beyond, while contributing to startup growth through experienced leadership in drug development and manufacturing.[1]
Chiasma is poised to expand its TPE™ pipeline into additional rare diseases and partnerships, leveraging Mycapssa's success amid surging oral biologics demand.[1][2] Trends like AI-driven drug discovery and peptide market growth to $50B+ by 2030 will shape its path, potentially amplifying influence through acquisitions or broader licensing.[1][3] As biopharma shifts to accessible therapies, Chiasma's injectable-to-oral pivot positions it as a key innovator, building on its funding momentum for sustained impact.
